Gujarat Themis Biosyn Limited
All news and filings related to Gujarat Themis Biosyn Limited.
View all news & filings- Medium impact
Gujarat Themis Biosyn Ltd. Issues Addendum to 45th AGM Notice, Proposes AoA Amendment
Gujarat Themis Biosyn Ltd. issued an addendum to its 45th AGM notice, scheduled for September 30, 2026. The addendum proposes amending Article 119 of its Articles of Association to allow Financial Institutions to appoint an observer instead of a Nominee Director, providing greater financing flexibility.
Read the summary - Low impact
Gujarat Themis Biosyn Announces 45th AGM on Sep 30, 2026, with E-voting Facility
Gujarat Themis Biosyn Limited will hold its 45th AGM on September 30, 2026. The company has provided a remote e-voting facility. The cut-off date for e-voting eligibility is September 23, 2026. The Register of Members will be closed from September 24-30, 2026.
Read the summary - High impact
Gujarat Themis Biosyn Announces 45th AGM on Sep 30, 2026, Approves Preferential Issue
Gujarat Themis Biosyn will hold its 45th AGM on September 30, 2026. The company proposes a preferential issue of equity shares worth ₹335 crore and plans to raise funds through loans and guarantees from promoters. Approvals are also sought for director commission payments and cost auditor remuneration.
Read the summary - High impact
Gujarat Themis Biosyn Approves Preferential Issue of ₹335 Crore Equity Shares
Gujarat Themis Biosyn approved a preferential issue of up to 82,10,786 equity shares at ₹408 each, raising approximately ₹335 crore. The funds will be raised via private placement from up to 5 investors, including promoter group entity Pharmaceutical Business Group (India) Limited.
Read the summary - Medium impact
Gujarat Themis Biosyn Approves QIP, Sets Issue Price at ₹354 Per Share
Gujarat Themis Biosyn Limited closed its QIP issue on August 28, 2026. The issue price is set at ₹354 per equity share, with a discount of 4.98% on the floor price. The company will allot 2,11,86,440 equity shares to QIBs.
Read the summary - Medium impact
Gujarat Themis Biosyn Approves Qualified Institutions Placement, Sets Floor Price at ₹372.57
Gujarat Themis Biosyn Limited's Board approved a Qualified Institutions Placement (QIP). The floor price is set at ₹372.57 per equity share, with a potential 5% discount. The QIP issuance was authorized following shareholder approval. The trading window is closed for designated persons.
Read the summary - Low impact
Gujarat Themis Biosyn Files Audited Financial Statements for FY 2026
Gujarat Themis Biosyn Limited has filed its audited financial statements for the fiscal year ending March 31, 2026. The company confirmed that its financial statements provide a true and fair view. Key audit matters included revenue recognition and asset management. The company has met its CSR obligations for the period.
Read the summary - Low impact
Gujarat Themis Biosyn Limited Amends Articles of Association Post Shareholder Approval
Gujarat Themis Biosyn Limited shareholders approved an amendment to the Articles of Association via postal ballot on August 22, 2026. The change removes the requirement for a registered valuer's report for share price determination in Article 13(1), Clause (c).
Read the summary - Low impact
Gujarat Themis Biosyn Amends Articles of Association Post EGM Approval
Gujarat Themis Biosyn Limited shareholders approved an amendment to the Articles of Association at an EGM on August 22, 2026. The change modifies Article 13(1) Clause (c) concerning share issuance terms.
Read the summary - Medium impact
Gujarat Themis Biosyn Ltd. Shareholders Approve Key Resolutions via Postal Ballot
Gujarat Themis Biosyn Limited shareholders approved three special resolutions via postal ballot and e-voting. Resolutions included fundraising through Qualified Institutions Placement, amendment to Articles of Association, and private placement of debt securities. All resolutions passed with requisite majority.
Read the summary - Medium impact
Gujarat Themis Biosyn Limited Successfully Passes All Resolutions at EGM
Gujarat Themis Biosyn Limited's EGM on August 22, 2026, passed resolutions for related party transactions, Articles of Association amendment, and debt securities private placement. All resolutions were approved by shareholders.
Read the summary - High impact
Gujarat Themis Biosyn Releases Q1 FY27 Earnings Call Transcript
Gujarat Themis Biosyn's Q1 FY27 revenue rose 22.1% YoY to ₹43.8 crore, with PAT at ₹11.1 crore. The company is expanding via acquisitions: MicroBiopharm Japan for fermentation tech and Sanofi brands for global reach. Investments in new fermentation and API capacity are complete, aiming for high-teen growth. Management targets becoming a leading fermentation-based CDMO.
Read the summary - Low impact
Gujarat Themis Biosyn: Investor Call Recording Available Online
Gujarat Themis Biosyn Limited has made the call recordings of its investor/analyst conference call, held on August 10, 2026, available on its website. The company provided a link to access the audio recordings as per SEBI regulations.
Read the summary - Low impact
Gujarat Themis Biosyn Announces Q1 FY27 Un-audited Financial Results
Gujarat Themis Biosyn Limited announced its unaudited standalone and consolidated financial results for the quarter ending June 30, 2026. The Board of Directors approved the results on August 7, 2026. The detailed financial statements and limited review report are available on the company's and stock exchanges' websites.
Read the summary - High impact
Gujarat Themis Biosyn Q1 FY27: Revenue up 22.1% to ₹43.8 Cr, PAT up 22.1% to ₹11.1 Cr
Gujarat Themis Biosyn reported Q1 FY27 revenue of ₹43.8 Cr, up 22.1% YoY. PAT grew 22.1% to ₹11.1 Cr, with EPS at ₹1.02. The company is progressing with acquisitions of Sanofi brands and MicroBiopharm Japan, and also investing in new R&D, API, and fermentation facilities in India, alongside a hybrid power plant.
Read the summary - Medium impact
Gujarat Themis Biosyn Q1 FY27 Results: Net Profit ₹1,106.67 Lakh
Gujarat Themis Biosyn reported Q1 FY27 results with total income at ₹4,392.16 lakh and net profit at ₹1,106.67 lakh. EPS stood at ₹1.02. The company also incorporated two subsidiaries outside India, though they have no operational impact yet.
Read the summary - Low impact
Gujarat Themis Biosyn to discuss 1QFY27 results on Aug 10
Gujarat Themis Biosyn will hold a conference call on August 10, 2026, at 14:30 IST to discuss its 1QFY27 financial performance. Key management will participate in the virtual meeting.
Read the summary - Low impact
Gujarat Themis Biosyn: Sachin D. Patel Acquires 5.23 Lakh Shares Worth ₹19.99 Crore
Sachin D. Patel acquired 5,23,560 shares of Gujarat Themis Biosyn Limited on July 30, 2026, for ₹19.99 crore at ₹382 per share. This inter-se promoter transfer increased his stake to 2.77%. The acquisition is exempt from open offer requirements under SEBI Takeover Regulations.
Read the summary - Low impact
Gujarat Themis Biosyn Limited Announces EGM on August 22, 2026
Gujarat Themis Biosyn Limited will hold its EGM on August 22, 2026, in Vapi, Gujarat. The meeting will address related party transactions, Articles of Association amendments, and NCD/debt security placements. Remote e-voting is open from August 19-21, 2026, with a cut-off date of August 15, 2026.
Read the summary - Medium impact
Gujarat Themis Biosyn: Indirect Share Encumbrance Disclosed Under Takeover Regulations
Gujarat Themis Biosyn Limited faces indirect share encumbrance. CTL Trusteeship Limited disclosed a pledge of 25.24 lakh shares and a non-disposal undertaking on 21.57 lakh shares of PBGIL, impacting Gujarat Themis Biosyn's shares. The encumbrances were created by VIPL effective June 29, 2026.
Read the summary - Low impact
Gujarat Themis Biosyn Publishes Newspaper Advertisement for Postal Ballot
Gujarat Themis Biosyn Limited published a newspaper advertisement on July 24, 2026, regarding a postal ballot. Members can cast their votes remotely from July 24, 2026, to August 22, 2026, on resolutions concerning fundraising via QIP, AoA amendment, and NCD/debt security placement. Results will be announced by August 25, 2026.
Read the summary - Medium impact
Gujarat Themis Biosyn to seek shareholder approval for ₹1,000 Crore QIP and NCD issuance
Gujarat Themis Biosyn is seeking shareholder approval to raise up to ₹1,000 crore via Qualified Institutions Placement (QIP) and up to ₹1,500 crore through NCDs/debt securities. Funds will be used for debt repayment, capex, working capital, and growth. E-voting runs from July 24 to August 22, 2026.
Read the summary - High impact
Gujarat Themis Biosyn's Credit Rating Placed on Watch with Negative Implications
Gujarat Themis Biosyn's bank facilities are on Rating Watch with Negative Implications due to significant acquisition plans totaling ~₹3,000 crore. The company aims to fund these via a ₹1,000 crore QIP. Acquisitions include MBJ for ¥1.5 Billion (~₹1,300 crore) and Sanofi brands for €158 million (~₹1,700 crore). GTBL disputes the rating, citing ongoing QIP and future revenue growth.
Read the summary - High impact
Gujarat Themis Biosyn's Credit Ratings Placed on Watch with Negative Implications
Gujarat Themis Biosyn's bank facilities are on Rating Watch with Negative Implications due to major acquisition plans: MBJ for ~₹1,300 crore and Sanofi brands for ~₹1,700 crore. Funding uncertainty, including a ₹1,000 crore QIP, is a concern. The company disputes the rating, citing ignored de-risking measures.
Read the summary - Medium impact
Gujarat Themis Biosyn: Sachin Patel to Acquire 0.50% Stake via Inter-se Promoter Transfer
Sachin D. Patel plans to acquire up to 5,25,000 equity shares of Gujarat Themis Biosyn Limited from Pharmaceutical Business Group (India) Limited between July 21-31, 2026. The acquisition, valued at up to ₹20 Crores at ₹382 per share, represents a 0.50% stake. This is an inter-se promoter transfer.
Read the summary - Medium impact
Gujarat Themis Biosyn: Promoter Entity Creates Pledge & Non-Disposal Undertaking on PBGIL Shares
Vividhmargi Investments Private Limited created a pledge on 25.24 lakh shares and a non-disposal undertaking on 21.58 lakh shares of PBGIL. This results in an indirect encumbrance on 5.12 crore shares of Gujarat Themis Biosyn Limited, held by PBGIL, representing 47.02% of its capital.
Read the summary - Low impact
Gujarat Themis Biosyn Settles Arbitration with Optimus Drugs Amicably
Gujarat Themis Biosyn Limited has amicably settled its arbitration with Optimus Drugs Private Limited. The dispute has been resolved mutually, leading to the disposal of the arbitration. The company stated there will be no penalty or material financial impact from this settlement.
Read the summary - Medium impact
Gujarat Themis Biosyn Shareholders Approve Special Resolution for QIP Fundraising
Gujarat Themis Biosyn shareholders approved a special resolution for fundraising via Qualified Institutions Placement (QIP). The resolution passed with overwhelming majority through postal ballot and e-voting, with 99.9762% votes in favour overall.
Read the summary - Medium impact
Gujarat Themis Biosyn Limited Shareholders Approve Special Resolution for QIP
Gujarat Themis Biosyn Limited shareholders approved a special resolution for raising funds via Qualified Institutions Placement (QIP). The resolution passed with 99.9762% votes in favor. The company announced the voting results on July 10, 2026.
Read the summary - Low impact
Gujarat Themis Biosyn Limited Files SEBI Reg 74(5) Certificate for Q1FY27
Gujarat Themis Biosyn Limited filed a certificate under SEBI Regulation 74(5) for the quarter ended June 30, 2026. The company confirmed processing of dematerialised securities and updates to the register of members.
Read the summary - Medium impact
Gujarat Themis Biosyn Files Quarterly Depository Certificate and Voting Results
Gujarat Themis Biosyn filed a depository certificate for the quarter ended June 30, 2026. The company also passed a special resolution for raising funds via Qualified Institutions Placement (QIP) with 99.98% votes in favour. Promoters held 77,218,083 shares.
Read the summary - Low impact
Gujarat Themis Biosyn Files SEBI Compliance Certificate for Q1 FY27
Gujarat Themis Biosyn Limited submitted a SEBI compliance certificate for Q1 FY27. Shareholders approved raising funds via Qualified Institutions Placement with 99.98% of polled votes in favor. Total shares polled were 72.96%.
Read the summary - Low impact
Gujarat Themis Biosyn: Promoter Sachin Patel to Acquire Up to 0.50% Stake via Inter-se Transfer
Promoter Sachin D. Patel plans to acquire up to 0.50% stake (5,25,000 shares) in Gujarat Themis Biosyn Limited from Pharmaceutical Business Group (India) Limited. The transaction, valued at up to ₹20 Crores, will occur between July 8-14, 2026, at ₹395.75 per share. This is an inter-se transfer among promoters.
Read the summary - Medium impact
Sachin D. Patel Acquires 24.97 Lakh Shares of Gujarat Themis Biosyn
Sachin D. Patel acquired 24,97,190 equity shares of Gujarat Themis Biosyn Limited for ₹400.45 per share on June 30, 2026. This inter-se transfer among promoters increases Patel's stake to 2.29% and is made under SEBI Takeover Regulations exemption.
Read the summary - High impact
Gujarat Themis Acquires Sanofi's TB/Anti-Infective Portfolio for €158 Million
Gujarat Themis Biosyn Limited is acquiring Sanofi's Anti-Tuberculosis and Anti-Infectives portfolio for €158 million. This asset deal includes brands and marketing authorizations, expanding its reach to 59 countries. The company also announced its intent to acquire MicroBiopharm Japan for JPY 9.5 billion.
Read the summary - Low impact
Gujarat Themis Biosyn Incorporates Wholly Owned Subsidiary in Ireland
Gujarat Themis Biosyn Limited has incorporated a wholly owned subsidiary, Themis Biosyn Ireland Private Limited, in Ireland on May 29, 2026. The subsidiary is in the pharmaceutical industry with a share capital of 1,00,000 Euro.
Read the summary - Low impact
Gujarat Themis Biosyn Posts Audited Financial Results for FY26
Gujarat Themis Biosyn Limited announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results on May 25, 2026. Full details are available on the company and stock exchange websites.
Read the summary - High impact
Gujarat Themis Acquires Sanofi Brands, MicroBiopharm Japan
Gujarat Themis Biosyn Limited will acquire 13 brands from Sanofi for ~EUR 158 million and MicroBiopharm Japan for ~JPY 21.5 billion (~₹1,300 crore). Q4 FY26 revenue grew 17% YoY to ₹44.2 crore, with PAT at ₹10.9 crore. FY26 PAT was ₹46.68 crore.
Read the summary - Medium impact
Gujarat Themis Biosyn Board Approves FY26 Audited Results, Recommends 67% Dividend
Gujarat Themis Biosyn approved audited financial results for FY26. The Board recommended a final dividend of ₹0.67 per share, totaling ₹7.30 crore. The company also approved the appointment of a new cost auditor and a preferential issue of equity shares to non-promoters.
Read the summary - High impact
Gujarat Themis Biosyn to Acquire MicroBiopharm Japan for ₹1,300 Crore
Gujarat Themis Biosyn will acquire MicroBiopharm Japan for approximately ₹1,300 crore (JPY 21.5 billion). The deal aims to transform GTBL into a CDMO platform, leveraging MBJ's fermentation and biotechnology expertise. MBJ reported FY26 revenues of approximately ₹570 crore (JPY 9.5 billion). The acquisition is expected to close in Q2FY27.
Read the summary - High impact
Gujarat Themis Acquires MicroBiopharm Japan for ₹1,300 Crore
Gujarat Themis Biosyn Limited will acquire 100% of Japan's MicroBiopharm Japan for ₹1,300 Crores. The deal, funded by debt and equity, aims to enhance GTBL's CDMO capabilities. The acquisition is expected to close in Q2 FY2027, subject to regulatory approvals.
Read the summary - Medium impact
Gujarat Themis Biosyn Incorporates Wholly Owned Subsidiary in Japan
Gujarat Themis Biosyn Limited has incorporated a wholly-owned subsidiary named Themis Biosyn Japan Limited in Japan. The company received the Certificate of Registration on 20th May, 2026, with the incorporation date being 19th May, 2026.
Read the summary - Low impact
Gujarat Themis Biosyn Incorporates Wholly Owned Subsidiary in Japan
Gujarat Themis Biosyn Limited incorporated a wholly owned subsidiary, Themis Biosyn Japan Limited, in Japan on May 19, 2026. The subsidiary has a share capital of Ten Lakhs Yen and operates in the pharmaceutical industry. Gujarat Themis Biosyn Limited will hold 100% of its shares.
Read the summary - Low impact
Gujarat Themis Biosyn Publishes Newspaper Advertisement for Postal Ballot
Gujarat Themis Biosyn Limited is conducting a postal ballot via e-voting for members to approve increased borrowing limits and limits for loans/investments. The voting period is from May 6 to June 4, 2026. Results will be announced by June 8, 2026.
Read the summary - Medium impact
Gujarat Themis Biosyn Seeks Shareholder Approval for ₹3,500 Crore Borrowing Limit
Gujarat Themis Biosyn is seeking shareholder approval via postal ballot to increase its borrowing limit to ₹3,500 Crores. The company also plans to create charges on its assets for security. The remote e-voting period is from May 6 to June 4, 2026, with results by June 8, 2026.
Read the summary - High impact
Gujarat Themis Biosyn Acquires Sanofi's TB & Anti-Infective Portfolio for €158M
Gujarat Themis Biosyn Limited is acquiring Sanofi's global Anti-TB and Anti-Infective portfolio for approximately €158 Million. The acquired assets generated €62 Million in FY25 revenue and reach over 55 countries. This asset-light acquisition aims to enhance GTBL's global footprint and improve its margin profile.
Read the summary - High impact
Gujarat Themis Biosyn to Acquire Sanofi's Global Anti-TB Portfolio for €158 Million
Gujarat Themis Biosyn will acquire Sanofi's global anti-TB and anti-infective portfolio for €158 million. The deal includes 13 brands across 55+ countries, with net sales of €62 million in FY25. This asset-light acquisition aims for forward integration and is expected to close by end of Q3FY27.
Read the summary - High impact
Gujarat Themis Biosyn Acquires Sanofi's TB/Anti-infective Brands for Euro 158 Million
Gujarat Themis Biosyn will acquire 13 anti-TB and anti-infective brands from Sanofi for Euro 158 million. The deal, expected to close by December 2026, includes marketing authorizations and regulatory dossiers. The acquired portfolio generated Euro 62 million in sales in FY25, aiming to expand the company's global reach.
Read the summary - Medium impact
Gujarat Themis Biosyn Shareholders Approve Director Re-appointment and Related Party Transactions
Gujarat Themis Biosyn Limited shareholders approved the re-appointment of Mrs. Kirandeep Madan as an Independent Director and material related party transactions with Themis Medicare Limited. The special resolution for director re-appointment passed with 100% votes in favour, and the ordinary resolution for related party transactions also received majority approval.
Read the summary - Low impact
Gujarat Themis Biosyn: Promoters Confirm No Share Encumbrance in FY26
Gujarat Themis Biosyn Limited promoters confirmed no share encumbrance in FY26. Previous disclosures for FY23-24 and FY25-26 concerning pledged shares by Pharmaceutical Business Group (India) Ltd and Themis Medicare Ltd have been made. This is a regulatory disclosure under SEBI Takeover Regulations.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio